A decision by Canada’s Drug Agency will make it more difficult for Canadians to access a drug shown to slow Alzheimer’s disease in some people, says an Ottawa cognitive neurologist and researcher.

Americans are having a few regrets about their approach to child safety in the care of drug-using parents.

Disc Medicine is laying off about 20% of its workforce after the Food and Drug Administration denied its application for accelerated approval of its bitopertin treatment.

Neighborhood groups are mobilizing against any proposal that would bring supportive housing and addiction treatment to the campus.

An informational consumer overview of Zealthy's prescription hydroquinone program, including compounded medication status, FDA context, telehealth dermatology consultation details, subscription and ...

Neurogene received FDA Breakthrough Therapy Designation for NGN-401 in Rett Syndrome, driving a >25% share price surge. Click ...

The recommendations are not binding but offer the legislature a guide to what laws Alaska would need to offer care if ...

Pharmaceutical costs. U.S. employers are expecting an 11 to 12% increase in pharmacy costs in 2026, which outpaces the percentage gain in general healthcare costs projected. GLP-1s contribute to this, ...

Rare diseases are not actually that rare. Collectively they affect 500 million people around the world. Some, such as Huntington’s disease and sickle cell disease, affect many thousands, others only ...

After UCB’s Bimzelx scored five approvals just two years, the Belgian drugmaker has quickly made a blockbuster out of its ...

The first and only approved achondroplasia therapy to provide continuous systemic exposure to CNP over the weekly dosing intervalCommercial availability expected during early part of Q2 2026Rare Pedia ...

ViiV Healthcare presents data for two investigational HIV treatment therapies with potential for twice-yearly dosing: London Saturday, February 28, 2026, 13:00 Hrs [IST] ViiV Heal ...